(Q40632608)

2

1 reference

22 September 2017

Amit Bhargav

3

1 reference

22 September 2017

Warren D W Heston

4

1 reference

22 September 2017

Bob Huryk

5

1 reference

22 September 2017

Peter T Scardino

6

1 reference

22 September 2017

1 October 2002

1 reference

22 September 2017

1 reference

22 September 2017

53

1 reference

22 September 2017

95-100

1 reference

22 September 2017

2

1 reference

22 September 2017

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Ribonucleotide reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10138